MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY
PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)
PHASE 1 STUDY OF JNJ-67856633, A FIRST-IN-HUMAN MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL
PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS, SUBGROUP ANALYSIS FROM BRUIN WITH >3 YEARS FOLLOW-UP FROM START OF ENROLLMENT
GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY
RITUXIMAB-CONTAINING COMBINED MODALITY THERAPY IN LIMITED STAGE FOLLICULAR LYMPHOMA: MATURE FOLLOW UP AND DERIVATION OF A NOVEL PROGNOSTIC SCORE FROM THE TROG99.03 TRIAL
Prognostic impact of HLA-I neoantigen-specific CD8+ T cells in limited-stage follicular lymphoma
Glofitamab plus R-CHOP or polatuzumab vedotin-R-CHP is deliverable with high overall response in patients ≤65 years of age with high-risk DLBCL: Interim analysis of COALITION
Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini-CHOP in very elderly patients with newly diagnosed DLBCL
Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory B-cell malignancies
First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients with B-Cell Lymphoma
POLATUZUMAB, BENDAMUSTINE & RITUXIMAB EFFICACY IN RELAPSED/REFRACTORY TRIAL-INELIGIBLE LARGE B CELL LYMPHOMA PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY
